Natural variability in the HR-1 and HR-2 domains of HIV type 1 gp41 from different clades circulating in Italy

被引:9
作者
Razzolini, Francesca
Vicenti, Ilaria
Saladini, Francesco
Micheli, Valeria
Romano, Laura
Cargnel, Antonietta
Zazzi, Maurizio
机构
[1] Univ Siena, Microbiol Sect, Dept Mol Biol, I-53100 Siena, Italy
[2] L Sacco Hosp Vialba, Dept Infect Dis 2, Milan, Italy
关键词
D O I
10.1089/aid.2006.0273
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The human immunodeficiency virus type 1 ( HIV-1) HR-1 and HR-2 gp41 regions were sequenced in a total of 228 plasma or peripheral blood mononuclear cell samples obtained from an equal number of enfuvirtide-naive subjects for pol genotypic resistance testing in clinical practice. Phylogenetic analysis of the env sequences indicated that 102 belonged to subtype B and 95 to non-B subtypes ( 31 CRF02_AG, 21 F1, 14 C, 11 A1/A2/A3, 9 CRF01_AE, 9 others) while the remaining 31 were unique recombinant forms. There was considerable variability in the consensus sequence of different clades, particularly in HR-2. The HR-1 amino acid region 36-45, containing all of the enfuvirtide resistance mutations so far characterized, was well conserved except for position 42 where serine and asparagine were unevenly distributed in different subtypes. Enfuvirtide resistance mutations were not present in any sample, reinforcing the expectation that enfuvirtide is effective against many different HIV-1 clades and recombinants. However, some of the mutations outside the amino acid 36-45 region and provisionally suggested to play a role in modulating resistance were detected in a minority of cases. Molecular epidemiological surveys coupled with long-term observation of in vivo response to enfuvirtide and future fusion inhibitors are required to clarify the clinical significance of gp41 natural variability.
引用
收藏
页码:558 / 563
页数:6
相关论文
共 23 条
[1]
Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa [J].
Aghokeng, AF ;
Ewane, L ;
Awazi, B ;
Nanfack, A ;
Delaporte, E ;
Zekeng, L ;
Peeters, M .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) :430-433
[2]
Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment [J].
Aquaro, Stefano ;
D'Arrigo, Roberta ;
Svicher, Valentina ;
Di Perri, Giovanni ;
Caputo, Sergio Lo ;
Visco-Comandini, Ubaldo ;
Santoro, Mario ;
Bertoli, Ada ;
Mazzotta, Francesco ;
Bonora, Stefano ;
Tozzi, Valerio ;
Bellagamba, Rita ;
Zaccarelli, Mauro ;
Narciso, Pasquale ;
Antinori, Andrea ;
Perno, Carlo Federico .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (04) :714-722
[3]
Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor [J].
Baldwin, CE ;
Sanders, RW ;
Deng, YQ ;
Jurriaans, S ;
Lange, JM ;
Lu, M ;
Berkhout, B .
JOURNAL OF VIROLOGY, 2004, 78 (22) :12428-12437
[4]
HIV entry inhibitors: mechanisms of action and resistance pathways [J].
Briz, V ;
Poveda, E ;
Soriano, V .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) :619-627
[5]
Natural resistance-associated mutations to enfuvirtide (T20) and polymorphisms in the gp41 region of different HIV-1 genetic forms from T20 naive patients [J].
Carmona, R ;
Pérez-Alvarez, L ;
Muñoz, M ;
Casado, G ;
Delgado, E ;
Sierra, M ;
Thomson, M ;
Vega, Y ;
de Parga, EV ;
Contreras, G ;
Medrano, L ;
Nájera, R .
JOURNAL OF CLINICAL VIROLOGY, 2005, 32 (03) :248-253
[6]
Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors [J].
Chinnadurai, R ;
Münch, J ;
Kirchhoff, F .
AIDS, 2005, 19 (13) :1401-1405
[7]
Analysis of genetic variability within the immunodominant epitopes of envelope gp41 from human immunodeficiency virus type 1 (HIV-1) group M and its impact on HIV-1 antibody detection [J].
Dorn, J ;
Masciotra, S ;
Yang, CF ;
Downing, R ;
Biryahwaho, B ;
Mastro, TD ;
Nkengasong, J ;
Pieniazek, D ;
Rayfield, MA ;
Hu, DJ ;
Lal, RB .
JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :773-780
[8]
Resistance to enfuvirtide, the first HIV fusion inhibitor [J].
Greenberg, ML ;
Cammack, N .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :333-340
[9]
Resistance mutation in HIV entry inhibitors [J].
Hanna, SL ;
Yang, CF ;
Owen, SM ;
Lal, RB .
AIDS, 2002, 16 (12) :1603-1608
[10]
Johnson Victoria A, 2006, Top HIV Med, V14, P125